FINOX Biotech (Finox AG) announced today the FORWARD initiative. FORWARD (Finox Offers Research Work Award in Reproductive Development) is a EUR 1 million fertility research grant offered over the next five years for innovative research proposals in reproductive medicine. The grant is open to applications by any reproductive research institutions and IVF centres in Europe.
Over the next five years Finox Biotech will invest EUR 1 million in research grants for innovative research programmes to improve fertility treatments to the benefit of patients seeking to become parents. The grants will be awarded to the host institution, which will take on the management of the fund to support the research study.
Gavin Jelic-Masterton, CEO of Finox Biotech commented, “The initiation of the FORWARD programme demonstrates the commitment of Finox Biotech to the fertility area – through a combination of our long-term investment over five years and our desire to fund and be involved in innovative research programs to enable the further development of this therapeutic area for the benefit of patients seeking to become parents. Finox Biotech takes this commitment very seriously and by offering EUR 1 million over the next five years we will further strengthen our scientific stature in fertility.”
The application closing date for the first round of funding is 15 November 2015. There will be a series of reviews following which shortlisted applicants will be notified by 30 January and given further details. The public announcement of winners will be made at ESHRE 2016 and the successful applicants will know the results by 30 March 2016. For further information on FORWARD and how to apply, please contact FORWARD@finoxbiotech.com or visit http://www.finoxbiotech.com/FORWARD.
About FINOX Biotech
FINOX Biotech (FINOX AG) is a biopharmaceutical company with its corporate headquarters in Burgdorf, Switzerland. FINOX Biotech was founded in 2007 with a vision to become a leading company in the field of fertility therapies, by combining high quality Swiss medicines with innovative and award winning delivery devices.
Over the next five years Finox Biotech will invest EUR 1 million in research grants for innovative research programmes to improve fertility treatments to the benefit of patients seeking to become parents. The grants will be awarded to the host institution, which will take on the management of the fund to support the research study.
Gavin Jelic-Masterton, CEO of Finox Biotech commented, “The initiation of the FORWARD programme demonstrates the commitment of Finox Biotech to the fertility area – through a combination of our long-term investment over five years and our desire to fund and be involved in innovative research programs to enable the further development of this therapeutic area for the benefit of patients seeking to become parents. Finox Biotech takes this commitment very seriously and by offering EUR 1 million over the next five years we will further strengthen our scientific stature in fertility.”
The application closing date for the first round of funding is 15 November 2015. There will be a series of reviews following which shortlisted applicants will be notified by 30 January and given further details. The public announcement of winners will be made at ESHRE 2016 and the successful applicants will know the results by 30 March 2016. For further information on FORWARD and how to apply, please contact FORWARD@finoxbiotech.com or visit http://www.finoxbiotech.com/FORWARD.
About FINOX Biotech
FINOX Biotech (FINOX AG) is a biopharmaceutical company with its corporate headquarters in Burgdorf, Switzerland. FINOX Biotech was founded in 2007 with a vision to become a leading company in the field of fertility therapies, by combining high quality Swiss medicines with innovative and award winning delivery devices.
